Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products ...

FDA reviews TNX-102 SL for Fibromyalgia by August 2025, with no advisory required. See why we recommend a buy on TNXP stock.

Tonix Pharmaceuticals (TNXP) announced the launch of TONIX ONE, a fully-integrated digital platform designed to help patients better understand ...

Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, emphasized the company’s innovative efforts to improve patient access to necessary medications. He stated that TONIX ONE ...

Tonix Pharmaceuticals (NASDAQ: TNXP) , a biopharmaceutical company advancing innovative therapies, announced the launch of TONIX ONETM, a fully integ ...

CHATHAM, NJ / ACCESS Newswire / March 31, 2025 /This post was written and published as a collaboration between the in-house ...

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 11.27%, which has investors questioning if this is right time to buy.

Tonix Pharmaceuticals shares are trading higher by 22.5% during Monday's session. The company announced that the FDA will not ...

Tonix Pharma (TNXP) has submitted an NDA for its candidate TNX-102 SL for fibromyalgia, with a PDUFA date set for August 15, 2025. See why I'm on the sidelines.

Tonix Pharmaceuticals (NASDAQ: TNXP) is gaining attention as it advances TNX-102 SL, a non-opioid investigational therapy for fibromyalgia, toward po ...

Shares of Tonix Pharmaceuticals are pulling back 12.7% during Thursday's session. The stock is pulling back following a regulatory update on its experimental fibromyalgia treatment, TNX-102 SL.

The biotechnology sector has experienced a jolt of volatility over the past few days, spearheaded by the dramatic price ...